Trial
NCT01797965
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
AbbVie
Condition
Relapsing-Remitting Multiple Sclerosis
Intervention
BIIB019 (Daclizumab)
Why stopped
Study terminated because of differences in the participant population under study compared with indicated Zinbryta use in most countries.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-04